Literature DB >> 3719895

Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer.

P Gunvén, N O Theve, C Peterson.   

Abstract

Blood and tissue concentrations of doxorubicin (DOX) were assayed after an intraoperative IV test dose of either free DOX 10 mg or its DNA complex 10 mg to patients with gastrointestinal cancer. After administration of the free drug, blood DOX levels decreased in an at least biphasic way, while DOX-DNA gave higher blood concentrations, which decreased slowly with no clear inflexion point on the concentration-time curve within the first hour. Tissue concentrations of DOX did not differ significantly after the two forms of the drug, liver being the tissue with the highest levels, followed by lymph node metastases, tumor tissue, muscle, and normal intestinal mucosa. If skeletal muscle can be used as a substitute for myocardium, lower cardiotoxicity of DOX-DNA than of DOX is not likely to be due to a difference in tissue uptake and retention between the two forms of DOX.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3719895     DOI: 10.1007/bf00306745

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Chemotherapy through lysosomes with a DNA-daunorubicin complex.

Authors:  A Trouet; D Deprez-de Campeneere; C De Duve
Journal:  Nat New Biol       Date:  1972-09-27

2.  Experimental evidence of characteristic tissue distribution of adriamycin. Tissue DNA concentration as a determinant.

Authors:  T Terasaki; T Iga; Y Sugiyama; M Hanano
Journal:  J Pharm Pharmacol       Date:  1982-09       Impact factor: 3.765

3.  Early-phase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters.

Authors:  J Robert; B Hoerni; P Vrignaud; C Lagarde
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin.

Authors:  J H Peters; G R Gordon; D Kashiwase; E M Acton
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Comparison of adriamycin-induced nucleolar segregation in skeletal muscle, cardiac muscle, and liver cells.

Authors:  J Merski; Y Daskal; H Busch
Journal:  Cancer Treat Rep       Date:  1978-05

6.  Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.

Authors:  R Hulhoven; G Sokal; C Harvengt
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration.

Authors:  Y T Lee; K K Chan; P A Harris; J L Cohen
Journal:  Cancer       Date:  1980-05-01       Impact factor: 6.860

8.  Plasma levels of doxorubicin after IV bolus injection and infusion of the doxorubicin-DNA complex in rabbits and man. Comparison with free doxorubicin.

Authors:  R Baurain; D Deprez-De Campeneere; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.

Authors:  A Ferrant; R Hulhoven; A Bosly; G Cornu; J L Michaux; G Sokal
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

10.  Time dependency of adriamycin and adriamycinol kinetics.

Authors:  P Gil; R Favre; A Durand; A Iliadis; J P Cano; Y Carcassonne
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more
  8 in total

Review 1.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

2.  A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts.

Authors:  Hua He; Can Liu; Yun Wu; Xinyuan Zhang; Jianghong Fan; Yanguang Cao
Journal:  Pharm Res       Date:  2018-07-09       Impact factor: 4.200

3.  Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy.

Authors:  S Stallard; J G Morrison; W D George; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans.

Authors:  Jianmin Duan; Gordon Bolger; Michel Garneau; Ma'an Amad; Joëlle Batonga; Hélène Montpetit; François Otis; Martin Jutras; Nicole Lapeyre; Manon Rhéaume; George Kukolj; Peter W White; Richard C Bethell; Michael G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

5.  Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.

Authors:  Thomas M Bodenstine; Grace S Chandler; David W Reed; Naira V Margaryan; Alina Gilgur; Janis Atkinson; Nida Ahmed; Matthew Hyser; Elisabeth A Seftor; Luigi Strizzi; Mary J C Hendrix
Journal:  Cell Cycle       Date:  2016-05-02       Impact factor: 4.534

6.  PTTG1 attenuates drug-induced cellular senescence.

Authors:  Yunguang Tong; Weijiang Zhao; Cuiqi Zhou; Kolja Wawrowsky; Shlomo Melmed
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

7.  Modulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro.

Authors:  Tamas Vancsik; Gertrud Forika; Andrea Balogh; Eva Kiss; Tibor Krenacs
Journal:  Cancer Med       Date:  2019-06-10       Impact factor: 4.452

8.  Cardiac spheroids as promising in vitro models to study the human heart microenvironment.

Authors:  Liudmila Polonchuk; Mamta Chabria; Laura Badi; Jean-Christophe Hoflack; Gemma Figtree; Michael J Davies; Carmine Gentile
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.